Literature DB >> 2964948

Clinical outcome 5 years after attempted percutaneous transluminal coronary angioplasty in 427 patients.

J D Talley1, J W Hurst, S B King, J S Douglas, G S Roubin, A R Gruentzig, H V Anderson, W S Weintraub.   

Abstract

This study was performed to define the 5 year clinical status of 427 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) in 1981. Their mean age was 54 +/- 10 years (+/- 1 SD). Sixty-one percent had unstable angina, 23% had prior myocardial infarction, 86% had one-vessel disease, and 92% had normal left ventricular function. Sixty-seven percent of patients had left anterior descending artery stenosis. Angiographic success was achieved in 84% of patients. Coronary bypass surgery was required in 9.6% of patients, in 5.9% as an emergency procedure. There were no in-hospital deaths. Follow-up at 5 years was 100% complete. There were 15 late deaths (96.3 +/- 1.0% survival), including seven of cardiac cause (98.1 +/- 0.7% cardiac survival). Myocardial infarction occurred in 24 patients (94% freedom from myocardial infarction), coronary bypass surgery was required in 63 (84% freedom from bypass surgery), and 365 patients (85%) were asymptomatic at follow-up. At 5 years, 83 patients (20%) had required an additional PTCA. Unstable angina pectoris and proximal left anterior descending coronary artery stenoses were present in 162 patients. The overall survival and cardiac survival in this subset was 94.4 +/- 1.8% and 98.1 +/- 1.1%, respectively. The excellent survival and low event rates over 5 years in this population support the concept that PTCA is safe and effective for patients with symptomatic angina pectoris, single-vessel disease, and normal left ventricular function.

Entities:  

Mesh:

Year:  1988        PMID: 2964948     DOI: 10.1161/01.cir.77.4.820

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  Cardiology.

Authors:  L D Smith; D J Coltart
Journal:  Postgrad Med J       Date:  1990-04       Impact factor: 2.401

2.  Risk stratification after percutaneous transluminal coronary angioplasty.

Authors:  J R Burton; M Haraphongse; L Hsu; C T Kappagoda; R E Rossall; B Schlaut; M P Senaratne
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

3.  Coronary angioplasty in the United Kingdom. Report of a Working Party of the British Cardiac Society.

Authors: 
Journal:  Br Heart J       Date:  1991-10

4.  Plaque modification and stabilization after paclitaxel-coated balloon treatment for de novo coronary lesions.

Authors:  Ae-Young Her; Eun-Seok Shin; Ju-Hyun Chung; Yong Hoon Kim; Scot Garg; Joo Myung Lee; Joon-Hyung Doh; Chang-Wook Nam; Bon-Kwon Koo
Journal:  Heart Vessels       Date:  2019-01-30       Impact factor: 2.037

5.  The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.

Authors:  M Texter; R S Lees; B Pitt; R E Dinsmore; A C Uprichard
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

6.  Anatomical and Physiological Changes after Paclitaxel-Coated Balloon for Atherosclerotic De Novo Coronary Lesions: Serial IVUS-VH and FFR Study.

Authors:  Soe Hee Ann; Gillian Balbir Singh; Kyung Hun Lim; Bon-Kwon Koo; Eun-Seok Shin
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.